Drug reference

Lamivudine with dolutegravir

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 712

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

HIV-1 infection ▶BY MOUTH ▶Adult: 300/50 mg once daily DOSE EQUIVALENCE AND CONVERSION ▶Dose expressed as x/y mg lamivudine/dolutegravir.

PDF page 712

National Funding Access Decisions

Scottish Medicines Consortium (SMC) decisions SMC No. SMC2205 The Scottish Medicines Consortium has advised (September 2019) that lamivudine with dolutegravir (Dovato ®) is accepted for use within NHS Scotland for the treatment of HIV-1 infection in adults and adolescents aged 12 years or older, weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower. All Wales Medicines Strategy Group (AWMSG) decisions AWMSG No. 3659 The All Wales Medicines Strategy Group has advised (February 2020) that lamivudine with dolutegravir (Dovato ®) is recommended as an option for use within NHS Wales for the treatment of HIV-1 infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

PDF page 712

Safety

Interactions

→Appendix 1: dolutegravir. lamivudine

PDF page 712

Renal Impairment

Manufacturer advises avoid if creatinine clearance less than 50 mL/minute.

PDF page 712

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Tablet A ▶Lamivudine with dolutegravir (non-proprietary) Dolutegravir (as Dolutegravir sodium) 50 mg, Lamivudine 300 mg Dovato 50mg/300mg tablets | 30 tablet P £656.26

PDF page 712

Clinical care

Patient And Carer Advice

Missed doses Manufacturer advises if a dose is more than 20 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

PDF page 712

Dose text by age group

Adult

300/50 mg once daily

First-line fragment. Read the complete Indications and Dose section above.

PDF page 712

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Lamivudine with dolutegravir

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 712

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

HIV-1 infection ▶BY MOUTH ▶Adult: 300/50 mg once daily DOSE EQUIVALENCE AND CONVERSION ▶Dose expressed as x/y mg lamivudine/dolutegravir.

PDF page 712

National Funding Access Decisions

PDF page 712

Safety

Interactions

→Appendix 1: dolutegravir. lamivudine

PDF page 712

Renal Impairment

Manufacturer advises avoid if creatinine clearance less than 50 mL/minute.

PDF page 712

Dose and formulations

Medicinal Forms

PDF page 712

Clinical care

Patient And Carer Advice

Missed doses Manufacturer advises if a dose is more than 20 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

PDF page 712

Dose text by age group

Adult

300/50 mg once daily

First-line fragment. Read the complete Indications and Dose section above.

PDF page 712

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.